Skip to Content

'
Jade Homsi, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit 430
Houston, TX 77030
Phone: 713-792-2921
Fax: 713-745-1046

Education & Training

Degree-Granting Education

1995 University of Damascus Medical School, Damascus, Syria, MD, Medicine

Postgraduate Training

7/2004-6/2007 Fellowship, Hematology & Medical Oncology, H. Lee Moffitt Cancer Research Institute, University of South Florida, Tampa, FL
7/2001-6/2004 Residency, Internal Medicine, St. John's Mercy Medical Center, St. Louis, MO
3/1998-6/2001 Research Fellowship, Medical Oncology-Palliative Medicine, The Cleveland Clinic Foundation, Cleveland, OH

Board Certifications

2007 Medical Oncology
2004 Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. e-Pub 6/2009. PMID: 19521262.
2. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. Am J Clin Oncol. e-Pub 6/2009. PMID: 19506454.
3. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 19(3):167-75, 6/2009. PMID: 19434004.
4. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma. Cancer Invest. e-Pub 5/2009. PMID: 19440934.
5. Naughton M, Homsi J. Symptom assessment in cancer patients. Curr Oncol Rep 4(3):256-263, Jan-Feb, 2002. PMID: 11937017.
6. Homsi J, Luong D. Symptoms and survival in patients with advanced disease. J Palliat Med 10(4):904-9, Jul-Aug, 2007. PMID: 17803412.
7. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 11(1):91-100, Jul-Aug, 2007. PMID: 17150037.
8. Homsi J, Daud AI. Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors. Cancer Control 14(3):285-94, Jul-Aug, 2007. PMID: 17615535.
9. Homsi J, Garrett C. Melanoma of the anal canal: A case series. Dis Colon Rectum 50(7):1004-10, Jul-Aug, 2007. PMID: 17468984.
10. Homsi J, Simon GR, Garrett CR, Springett G, DeConti R, Chiappori AA, Munster PN, Burton M, Stormat S, Allievi C, Eisenfeld A, Sullivan DM, Daud AI. Phase I trial of poly L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 13(19):5855-61, 10/2007.
11. Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, Davis M, Naughton M, Gvozdjan D, Pham H. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer 14(5):444-53, Jul-Aug, 2006. PMID: 16402231.
12. Homsi J, Garrett C. Hepatic arterial infusion of chemothepary for hepatic metastases from colorectal cancer. Cancer Control 13(1):42-7, 2006.
13. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control 12(4):223-229, Jul-Aug, 2005. PMID: 16258493.
14. Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M, Khawam E, Nouneh C. The impact of palliative medicine consultation service in medical oncology. Support Care Cancer 10:337-342, 2002.
15. Cowan JD, Walsh D, Homsi J. Palliative medicine in a United States cancer center: a prospective study. Am J Hosp Palliat Care 19(4):240-50, Jul-Aug, 2002. PMID: 12141788.
16. Homsi J, Walsh D, Nelson KA, Sarhill N, Rybicki L, Legrand SB, Davis MP. A phase II study of hydrocodone for cough in advanced cancer. Am J Hosp Palliat Care 19(1), Jan-Feb. e-Pub 2002. PMID: 12171425.
17. Davis MP, Homsi J. The importance of cytochrome P450 mono-oxygenase CYP2D6 in palliative medicine. Support Care Cancer 9:442-451, 2001.
18. Sarhill N, Walsh D, Nelson KA, Homsi J, LeGrand SB, Davis M. Methylphenidate for fatigue in advanced cancer: prospective open-label pilot study. Am J Hosp Palliat Care 18(3):187-192, 2001.
19. Homsi J, Walsh D, Nelson KA. Important drugs for cough in advanced cancer. Support Care Cancer 9(8):565-574, Nov-Dec, 2001. PMID: 11762966.
20. Homsi J, Nelson KA, Sarhill N, Rybicki L, LeGrand SB, Davis MP, Walsh D. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 18(6):403-407, Nov-Dec, 2001. PMID: 11712722.
21. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer 8(5):385-397, 2000. PMID: 10975688.
22. Homsi J, Walsh D, Nelson KA, LeGrand S, Davis M. Methylphenidate for depression in hospice practice: a case series. Am J Hosp Palliat Care 17(6):393-398, Nov-Dec, 2000. PMID: 11886041.
23. Homsi J, Walsh D, Panta R, Lagman R, Nelson KA, Longworth D. Infectious complications in advanced cancer. Supportive Care in Cancer 8(6):487-492, 2000.
24. Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M. Hydrocodone for cough in advanced cancer. Am J Hosp Palliat Care 17(5):342-346, Sep-Oct, 2000. PMID: 11886059.
25. Komurcu S, Nelson KA, Walsh D, Donnelly SM, Homsi J, Abdullah O. Common symptoms in advanced cancer. Semin Oncol 27(1):24-33, 2000. PMID: 10697019.
26. Nelson KA, Walsh D, Abdullah O, McDonnell F, Homsi J, Komurcu S, LeGrand SB, Zhukovsky DS. Common complications in advanced cancer. Semin Oncol 27(1):34-44, 2000.
27. Sarhill N, Walsh D, Nelson K, Homsi J, Komurcu S. Bioelectrical impedance, cancer nutritional assessment, and ascites. Support Care Cancer 8(4):341-343, 2000. PMID: 10923777.

Book Chapters
1. Homsi J. Rethinking Phase I trials: Going beyond toxicity in evaluating new agents. In: ASCO Educational Book, 172-175, 2007.

Grant & Contract Support

Title: A multicenter, open-label, phase I/II study of GMX1777 in combination with Temozolomide administered every 4 weeks to patients with metastatic melanoma
Funding Source: Gemin X Pharmaceuticals
Role: Principal Investigator
Duration:
 
Title: Phase III trial of ABI-007 vs Dacarbazine in previously untreated patients with metastatic malignant melanoma
Funding Source: Abraxis Oncology
Role: Principal Investigator
Duration:
 
Title: A phase II, open-label, single-arm, multicenter study evaluating the safety and antitumor activity of IPI-504, a novel small molecule inhibitor of heat shock protein 90 (HSP90), in patients with metastatic melanoma
Funding Source: MedImmune, Inc.
Role: Principal Investigator
Duration: 5/23/2008 - 12/31/2008

Last updated: 8/31/2009